Intraday Data provided by FACTSET and subject to terms of use. Spark Therapeutics has a market capitalization of $4.38 billion and generates $64.72 million in revenue each year. By Martin Baccardax. Get short term trading ideas from the MarketBeat Idea Engine. Stock analysis for Spark Therapeutics Inc (ONCE) including stock price, stock chart, company news, key statistics, fundamentals and company profile. High institutional ownership can be a signal of strong market trust in this company. The official website for Spark Therapeutics is www.sparktx.com. Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts. Tickers BMRN ESRX ONCE. There are currently no items in this Watchlist. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. Our ONCE ETF report shows the ETFs with the most ONCE exposure, the top performing ONCE ETFs, and most popular ONCE ETF strategies. Spark Therapeutics is registered under the ticker NASDAQ:ONCE . View real-time stock prices and stock quotes for a full financial overview. Have Watchlists? Brookside Capital and Sofinnova Investments are the most recent investors. (Add your “underperform” vote.). The company's product candidates are in the field of retina-directed gene therapies, liver-directed gene therapies, and central nervous system therapies. Spark Therapeutics, Inc. | 41.206 volgers op LinkedIn. View today's stock price, news and analysis for Spark Therapeutics Inc. (ONCE). It is a subsidiary of Hoffmann-La Roche History. In terms of relative price strength - which takes into account the overall market trend - the Spark Therapeutics Inc price has moved by 0.142k% over the past year. Spark Therapeutics, a unit of Roche Holdings (OTC: RHHBY), has announced preliminary data from part one of the ongoing Phase 1/2 trial evaluating SPK … Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The major Spark Therapeutics (ONCE) merger news updates & events are listed below. Spark Therapeutics is funded by 7 investors. View which stocks are hot on social media with MarketBeat's trending stocks report. Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts. Privacy Notice, and Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. The following information was filed by Spark Therapeutics, Inc. (ONCE) on Tuesday, February 19, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. The company was founded in 2013 by Katherine A. Earnings for Spark Therapeutics are expected to grow in the coming year, from ($5.07) to ($4.34) per share. All rights reserved. Tags Price Target Analyst Color Blindness. Learn more. Spark Therapeutics Inc., which hopes to turn decades of gene-therapy research at Children's Hospital of Philadelphia into commercial cures for diseases, has filed papers to conduct an initial public stock offering. Spark Therapeutics has received 53.95% “outperform” votes from our community. Spark Therapeutics, Inc. (US:ONCE) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. Feb 25, 2019 11:37 AM EST. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. We were born of innovation, springing from the curiosity, imagination and dedication of remarkable scientists and healthcare visionaries. January 03, 2018. View Spark Therapeutics' earnings history. The major Spark Therapeutics (ONCE) merger news updates & events are listed below. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]. Spark Therapeutics Inc (NASDAQ:ONCE) was in 36 hedge funds' portfolios at the end of September. Brookside Capital and Sofinnova Investments are the most recent investors. It is focused on debilitating genetic diseases by developing one-time, life-altering treatments. Only 6.00% of the stock of Spark Therapeutics is held by insiders. Spark Therapeutics will continue to operate as an independent company within the Roche Group. Some companies that are related to Spark Therapeutics include Novozymes A/S (NVZMY), argenx (ARGX), Bio-Techne (TECH), Novavax (NVAX), QIAGEN (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Acceleron Pharma (XLRN), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Kodiak Sciences (KOD), Vir Biotechnology (VIR), Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT). For the best MarketWatch.com experience, please update to a modern browser. Will Editas Medicine's CEO Change Help or Hurt? View the latest Spark Therapeutics Inc. (ONCE) stock price, news, historical charts, analyst ratings and financial information from WSJ. An invaluable data source for traders & investors looking to familiarize themselves with the Roche (RHHBY) takeover of Spark Therapeutics (ONCE) and trade the merger arbitrage spread.Following the acquisition news and events section, there is in-depth company profile. Spark Therapeutics has raised a total of $122.8M in funding over 2 rounds. Approached $1 Trillion in 2019, Surpassing Cost Estimates for Many Chronic Diseases, 4 Top Penny Stocks To Buy Under $3? Spark Therapeutics, Inc. focuses on the development of gene therapy products. January 16, 2018. Company Name: Spark Therapeutics Inc., Stock Symbol: ONCE, Industry: Biotechs, Total Posts: 124, Last Post: 2/27/2019 2:49:10 PM Their latest funding was raised on May 27, 2014 from a Series B round. Price to Earnings Ratio vs. Sector Spark Therapeutics (NASDAQ:ONCE) recently updated investors on the clinical-trial performance of its gene therapy for hemophilia A. Wall Street Reacts To Spark Therapeutics' $850K Genetic Blindness Treatment. Something went wrong while loading Watchlist. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Spark Therapeutics has received 519 “outperform” votes. Spark Therapeutics, Inc is primarely in the business of biological products (no diagnostic substances). Looking for new stock ideas? Their latest funding was raised on May 27, 2014 from a Series B round. (ONCE) raised $88 million in an initial public offering (IPO) on Friday, January 30th 2015. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Feb 25, 2019 11:37 AM EST. Analyst: Spark Therapeutics' $850K Blindness Drug Has Smaller-Than-Expected Market. Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. Vote “Underperform” if you believe ONCE will underperform the S&P 500 over the long term. Create a list of the investments you want to track. Learn more. Spark Therapeutics does not have a long track record of dividend growth. Kristine Harjes: First, Spark Therapeutics, ticker ONCE, lost 28% of its market cap on Tuesday of last week. Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. The Stock Performance of Spark Therapeutics, Inc, is significantly lower than the stock performance of its index. On Tuesday, shares of Spark Therapeutics recorded a trading volume of 646,612 shares, which was above the three months average volume of 560,567 shares. Spark Therapeutics Inc (NASDAQ:ONCE) was in 36 hedge funds' portfolios at the end of September. Fisker stock jumps after passing 14K reservations for Ocean SUV electric vehicle, Iowa’s Republican governor signs bill reducing early voting, cutting polling-station hours, curbing absentee voting, Tennessee Republicans seek to oust judge who OK’d expansion of absentee voting amid pandemic, Georgia Senate passes bill to eliminate no-excuse absentee voting, Target to launch new food and beverage brand, Favorite Day, in April, Dick's Sporting Goods stock slumps despite earnings beat, The stock market’s bulls are still in charge, Roche extends tender offer for Spark Therapeutics. Spark’s robust pipeline includes SPK-RPE65, a fully enrolled, pivotal Phase 3 program in blindness due to mutations in the RPE65 gene, SPK-CHM for the treatment of choroideremia, and SPK-FIX, a program for the potential treatment of hemophilia B through a global collaboration with Pfizer Inc., as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE.". © American Consumer News, LLC dba MarketBeat® 2010-2021. Could pandemic bring biotech businesses to Jupiter? Seeing the improvements in our patients motivates me to work towards the success of these genetic treatments. Spark Therapeutics is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law. By using this site you agree to the Vote “Outperform” if you believe ONCE will outperform the S&P 500 over the long term. Corporation Stock Makes a New Buy Case on Improving Analyst Picture, Big Lots Follows North Star To Profits, You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, Economic Burden of Rare Diseases in the U.S. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Log in to see them here or sign up to get started. An estimated 5,000 rare diseases are each caused by a single … Do Not Sell My Information. Spark a change in your career and join us! Get daily stock ideas top-performing Wall Street analysts. Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Netflix (NFLX), Pfizer (PFE) and (CELG). MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Want to see which stocks are moving? MARKETS. This video was recorded on Aug. 15, 2018. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. Earnings for Spark Therapeutics are expected to grow in the coming year, from ($5.07) to ($4.34) per share. Gene-Therapy Firm Audentes Sells for Double Its Share Price. Identify stocks that meet your criteria using seven unique stock screeners. Intraday data delayed at least 15 minutes or per exchange requirements. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The P/E ratio of Spark Therapeutics is -53.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. You may vote once every thirty days. MARKETS. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. | At Spark Therapeutics, we don’t follow footsteps. Stock Performance of Spark Therapeutics, Inc, ( ONCE | USA) The Stock Price change percentage is a relevant indicator for computing stock performance. ), Spark Therapeutics has received 443 “underperform” votes. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. We create the path. All quotes are in local exchange time. View the latest ONCE financial statements, income statements and financial ratios. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Spark Therapeutics is funded by 7 investors. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.